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Introduction
Pars plana vitrectomy (PPV) was introduced 
almost 40 years ago.1 In the 1980s and 
1990s, three-port PPV with 20-gauge (G) 
instruments was the norm. In 2002, 25-gauge 
transconjunctival sutureless vitrectomy (TSV) 
was introduced.2,3 This system permits three-
port PPV using microcannulas, trocars, and 
25-G instrumentation without requiring sutures 
to close the sclerotomies. Subsequently, a 
similar technique but with 23-G instruments 
was developed.4 Currently, 25- and 23-gauge 
systems constitute the two most popular TSV 
techniques.
Herein, we review the advantages and 
disadvantages of small-gauge vitreous surgery.
Instrumentation
TSV consists of a 23-G or 25-G microcannular 
system and a wide array of vitreoretinal 
instruments specifically designed for this 
operating system. The microcannula consists 
of a thin-walled tube, 4 mm in length. A collar 
is present at the extraocular portion, which 
can be grasped with a forceps to manipulate 
the microcannula. The insertion trocar has a 
sharp tip that forms a continuous bevel with 
the microcannula, allowing easy entry through 
the conjunctiva into the eye (Fig. 1). The 25-G 
infusion cannula consists of a small tube that 
fits neatly and can be directly inserted into 
the cannula in the inferotemporal quadrant. 
A wide array of vitreoretinal microsurgical 
instruments complying with 25-G standards 
has been designed. These include vitreous 
cutters, illumination probes, intraocular forceps, 
microvitreoretinal blades, tissue manipulators, 
aspirating picks, aspirators, soft-tip cannulas, 
curved scissors, extendable curved picks, 
intraocular laser probes, and diathermy   
probes.
Surgical Technique
Small gauge vitrectomy is usually performed 
with the patient under local anesthesia. 
General anesthesia is only performed in 
Figure 1. Insertion of 23-gauge trocars and 
microcannulas. The microcannulas are inserted through 
the conjunctiva into the eye by means of a trocar. Insertion 
is accomplished by first displacing the conjunctiva 
laterally by approximately 2 mm. An initially oblique, 
then perpendicular tunnel is made parallel to the limbus 
through the conjunctiva and sclera, thus creating a self-
sealing wound.Controversy; Sutureless Vitrectomy
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selected cases (children or uncooperative 
adults). After appropriate anesthesia, the 
operative field is prepared using antiseptic 
solutions. Preoperatively, the eyelash margins 
are scrubbed with povidone-iodine solution. 
The microcannulas are inserted through the 
conjunctiva into the eye by means of a trocar. 
Insertion is accomplished by first displacing 
the conjunctiva laterally by approximately 
2 mm. An initially oblique, then perpendicular 
tunnel is made parallel to the limbus through 
the conjunctiva and sclera creating a self-
sealing wound (Fig. 1). After insertion of the 
first microcannula, the intraocular portion of 
the infusion cannula is directly inserted into 
the external opening of the microcannula.5,6 
Once the intraocular position of the infusion 
cannula is verified, infusion is opened and the 
other two microcannulas are inserted in the 
superotemporal and superonasal quadrants for 
three-port PPV. At the completion of surgery, 
the microcannulas are simply removed by 
grasping the collar and withdrawing, along 
with assessment of intraocular pressure (IOP) 
and wound sites for possible leaks.
The 23-G system is a variation of the 25-G 
TSV system. 23-G vitreous cutters have been 
improved by placing the cutter opening nearer 
to the end of the probe allowing a closer vitreous 
shave. This increases safety near the retina. 
At the end of vitrectomy, adequate gas/air 
tamponade must be performed which avoids 
significant postoperative leakage in most cases. 
However, in some cases leakage may occur 
and the sclerotomy site should be closed with 
a single 7-0 or 8-0 vycril suture. In addition, 
sclerotomy sites are to be closed if silicone 
oil is used. The microcannulas can be simply 
removed by grabbing the external collar with 
a forceps at the end of the procedure. The last 
microcannula to be removed should be the one 
with the infusion line (Fig. 2). Postoperative 
subconjunctival injection of antibiotic and 
steroid solutions should be administered 
as in standard vitrectomy. Endophthalmitis 
is extremely uncommon following vitreous 
surgery, but there is a theoretical concern 
that 25-G sutureless surgery may pose an 
added risk.7 However, these concerns have 
subsided due to recent studies revealing a 
low incidence of endophthalmitis in a large 
series of patients undergoing small-gauge   
sutureless surgery.8
Advantages of Small‑gauge Vitrectomy
In general, TSV seems to be particularly 
advantageous for procedures that do not 
require extensive intraocular tissue dissection 
or manipulation. Experience has shown that 
25-gauge surgery is ideal for vitreous and 
preretinal hemorrhages in proliferative diabetic 
retinopathy (Fig. 3), rhegmatogenous retinal 
detachment, proliferative vitreoretinopathy 
(PVR), giant retinal breaks, and cases in 
which vitrectomy and phacoemulsification 
are combined with intraocular lens (IOL) 
Figure 2. After withdrawal of the cannula, a cotton tip 
applicator can be used to misalign the outer and inner 
aspects of the sclerotomies thereby reducing the risk of 
leakage.
Figure 3. Intraoperative photographs of a diabetic eye 
with vitreous and preretinal hemorrhages managed with 
23-gauge instrumentation.Controversy; Sutureless Vitrectomy
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implantation. It is also applicable for diabetic 
traction retinal detachment with moderate 
amounts of epiretinal membranes (ERMs), and 
idiopathic ERMs as well (Fig. 4). However, 
if scleral buckling or silicone oil tamponade 
is anticipated, standard 20-G vitrectomy is 
preferred as its full capability may be required 
in those cases. Even in complex cases where one 
needs a variety of scissors and forceps and/
or the injection of silicone oil, 25-G or 23-G 
sclerotomies can be used for the infusion and 
illumination probes, and a 20-G sclerotomy 
can be performed for the instruments and 
the injection and removal of silicone oil. This 
enables the surgeon to use 20-G instruments 
and reduce the cost of replacing all devices.9 
An alternative is to use 1000 centistoke silicone 
oil with 23-G instrumentation, therefore even 
complex cases can be resolved with small-
gauge surgery.
Another advantage of TSV becomes 
apparent in pediatric cases. Typically, newborn 
and premature eyes are significantly smaller 
than adult eyes and the use of standard 
vitreoretinal instruments may be technically 
difficult.10 With TSV, the intraocular instruments 
are more compatible with the smaller pediatric 
eyes and are efficient in selected cases of 
persistent fetal vasculature, retinopathy 
of prematurity, uveitis, and some cases of 
uncomplicated tractional or rhegmatogenous 
retinal detachments. In addition, TSV offers 
benefits in certain vitreoretinal cases because 
it is transconjunctival. TSV-based surgery has 
the potential to shorten operative time for a 
variety of procedures, and reduce postoperative 
inflammation at the sclerotomy sites (Fig. 5), 
thus reducing patient discomfort and hastening 
postoperative recovery. It also avoids induced 
astigmatism, allowing more rapid visual 
recovery.11
Disadvantages of Small‑gauge Vitrectomy
One disadvantage of this system is the learning 
curve required to achieve maximum efficiency. 
However, this curve is short enough for the 
adaptable surgeon. 
Due to its smaller fiberoptic size, illumination 
is also reduced with 25-gauge surgery. However, 
current systems provide adequate illumination 
in most cases. A noticeable difference of 25-G 
instruments is their marked flexibility.
There are some potential complications 
specifically related to the 25-gauge system, 
the most obvious being hypotony and a higher 
incidence of endophthalmitis.7 The risk of these 
complications can be reduced by creating a 
tunnel or angular incision in a different plane 
relative to the conjunctiva, and performing 
fluid-air exchange at the end of the surgery. 
It is important to note that hypotony is more 
common in previously vitrectomized eyes. As 
mentioned, these concerns have been diminished 
as a result of recent studies demonstrating 
a low incidence of endophthalmitis in large 
series of patients undergoing TSV.8 In terms of 
Figure 4. Intraoperative photograph of macular epiretinal 
membrane treated with 23-gauge instrumentation.
Figure 5. The microcannulas are inserted through the 
conjunctiva into the eye and 23-gauge instruments are in 
place at the sclerotomy sites.Controversy; Sutureless Vitrectomy
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prophylaxis, all patients undergoing 25-gauge 
vitrectomy should have standard and meticulous 
preparation with povidone-iodine, as well 
as postoperative injection of subconjunctival 
antibiotics. 
For a surgeon used to performing 20-G 
vitrectomy, transition to 23-G is easier than 
25-G. With the 23-G system, rigidity, flow and 
aspiration of the vitreous cutter are similar to 
the 20-G system, and lighting is comparable. 
The instruments have stiffness similar to 20-G. 
However the sclerotomies must be precisely 
formed, with tunnel or angular incisions to 
reduce complications.
Recent Advances in 23‑ and 25‑gauge Surgery: 
Overcoming the Disadvantages
Instrument Rigidity 
The lower rigidity of instruments is a problem 
with 25-G, these instruments are more pliable and 
more damageable, furthermore manipulation of 
the globe can become cumbersome. This is not 
an issue with 23-G, as rigidity is similar to 20-G 
(Fig. 5). Several companies are producing more 
rigid 25-G instruments (including the new Alcon 
Constellation system; Alcon Laboratories, Fort 
Worth, TX, USA) or are reducing instrument 
length to achieve the same purpose.
Instrument Availability
Initially, available instruments were limited to 
small-gauge forceps, however nowadays a full 
armamentarium of instruments is available in 
small-gauge, including extrusion cannulas for 
silicone oil injection and removal, scissors, dual-
bore cannulas for perfluorocarbon injection, 
diathermy probes, multidirectional laser probes, 
chandeliers, and 40-G cannulas for subretinal 
injections. In essence, at present, the same range 
of instruments used in 20-G, is available in 23- 
and 25-G, with the exception of a fragmatome. 
Nevertheless, several companies are working 
on developing a 23-G fragmatome to address 
dislocated nuclei, and DORC (Zuidland, The 
Netherlands) has recently released the 23-gauge 
Rayes Fragmentation Needle.
Illumination 
Since the number of light fibers is reduced, 
particularly with 25-G, brighter light sources 
are needed, such as Photon (Synergetics 
Inc., O’Fallon, MO, USA) and Xenon (Alcon 
Laboratories, Fort Worth, TX, USA). The new 
Alcon Constellation system has much brighter 
light than the actual Xenon. Bausch & Lomb 
(Rochester, NY, USA) uses the Photon. With 
these recent modifications, illumination is not 
much of an issue anymore.
Cutting Efficiency
Slow vitreous removal is a potential problem 
with 25-G, this issue has been addressed in 
the new Alcon Constellation machine. The 
new 25-G probe has a bigger opening and a 
longer duty cycle (the amount of time the port 
is open); these alterations allow an increased 
aspiration rate while maintaining high-speed 
cutting rates. The 23-G system will benefit 
from the same duty cycle improvement, but the 
probe is different and does not have a spring 
mechanism, so it can stay open longer during 
each cut, allowing greater aspiration. Thus the 
rapidity of vitreous removal with 23- and 25-G 
will be markedly improved. Cutting rates of 
up to 5000 cuts/min are available, allowing 
for shaving of the vitreous base and safer 
vitrectomy, even in detached retinas.
Wound Architecture 
Wound architecture is the most important aspect 
of TSV; complications such as endophthalmitis 
and retinal breaks are associated with badly 
fashioned wounds. Initially, wounds for 25-G 
vitrectomy were made by direct entry, this 
could have been the cause of hypotony and 
increased endophthalmitis rates among other 
complications. Displacement of the conjunctiva 
and a two-plane wound with fluid-air exchange 
at the end of the procedure, reduce wound leaks 
and decrease the risk of endophthalmitis and 
hypotony. The DORC and new Alcon 23-G TSV 
systems have a flat blade trocar system which 
produces a slit wound that closes better than Controversy; Sutureless Vitrectomy
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the actual chevron wound made by the round 
trocar blade system. Wound construction in 
our view is the most important aspect of TSV 
and the key point in the learning curve. One 
should always keep in mind that if any doubt 
exists regarding leakage, the surgeon should 
suture the sclerotomy site. Our threshold for 
tends to be lower in complicated cases where 
silicone oil needs to be used. 
Surgical Outcomes 
Other benefits of TSV include astigmatism-
neutral surgery, shortened operative time, less 
inflammation and reduced patient discomfort. 
We truly believe that the reportedly increased 
incidence of endophthalmitis is technique-
dependent. With adequate preoperative 
povidone-iodine preparation, good wound 
construction in two planes, a partial or total 
fluid-air exchange at the end of the procedure, 
and subconjunctival antibiotics, the risk of 
hypotony and endophthalmitis can be reduced.
Learning Curve 
The learning curve is mainly due to wound 
construction and for 25-G, the current lack of 
rigidity. The TSV 23-G system has less of a 
learning curve, as the instruments have similar 
rigidity as 20-G. The 23-G system has been more 
user-friendly due to the illumination, rigidity, 
and increased flow, which are all similar to 20-G. 
With improvements in 25-G systems, at least 
with the Constellation system, 25-G surgery 
will feel more like 23-G, as rigidity, aspiration, 
and illumination are increased significantly.
Summary
Cataract surgery was revolutionized by the 
introduction of phacoemulsification and foldable 
IOLs. This enabled a reduction in the size of 
the incision and avoided the necessity of using 
sutures. This transition shortened operative 
time, reduced complications, and increased 
patient satisfaction and comfort.
The same transition is occurring in 
vitreous surgery. Both vitrectomy techniques, 
either 25-G or 23-G, have been improving 
with time, experience, and the introduction 
of better instruments. Surgical indications are 
expanding with experience and the availability 
of new technology. Performing minimally 
invasive surgery has many advantages for 
both the surgeon and the patient. The reduced 
surgical time improves efficiency and also 
reduces complications and surgical trauma. 
Postoperative recovery is more rapid, since 
there is less inflammation. Technological 
developments, more efficient vitreous cutters, 
and a variety of 23-G and 25-G instruments 
have made small-gauge vitrectomy the gold 
standard and it is here to stay.
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CON
The large leap in surgery during the past few 
decades has been its progress towards becoming 
more minimal and less destructive. Laparoscopic 
surgery is a prototype of this change. This 
concept has also provided immense changes 
in ophthalmic surgical techniques: transition 
from intracapsular to extracapsular cataract 
surgery with implantation of IOLs, followed 
by less invasive phacoemulsification with 
foldable IOLs, and finally, minimally invasive 
cataract surgery.
But what about vitreoretinal procedures? 
Have these operations also moved in same 
direction of becoming less invasive and more 
minimal? With no doubt, the answer is yes. The 
change in buckling techniques from implants 
to explants, the trend to use segmental buckles 
instead of encircling elements, and the use of 
pneumatic retinopexy or vitrectomy instead of 
scleral buckling are all signs of attempts to do 
less extensive, but more effective procedures. 
One of the greatest changes in this field during 
the last two decades has been the introduction of 
minimally invasive vitreoretinal surgery (MIVS), 
which by using 23- or 25-gauge instruments, 
allows a sutureless procedure.1,2
Although most vitrectomy cases are 
suitable candidates for sutureless vitrectomy, 
not all patients can be handled “sutureless”. 
Examples include extraction of a large 
intraocular foreign body in a case with a clear 
lens, and eyes requiring scleral buckling in 
addition to vitrectomy. Clearly, these constitute 
only a minority of current vitrectomy cases. 
There are other situations in which the use 
of sutureless techniques with its small-gauge 
instruments still poses limitations, such as 
the absence of a full range of multifunctional 
instruments in small-gauge for complicated 
retinal detachments and diabetic retinopathy, 
flexibility of the instruments when maneuvers 
in the retinal periphery become necessary, 
inability to overcome dense thick membranes 
with small-gauge instruments, and the injection 
and removal of silicone oil, especially of 
high viscosity. In most of these situations, 
the case cannot be managed with self-sealing 
sclerotomies. 
I am aware of the fact that the mentioned 
limitations are being solved by technological 
advances and will no longer be a problem in 
the near future. But let’s look at the question 
from another perspective.
The question whether sutureless vitrectomy 
is the future of vitreoretinal surgery is similar 
to asking whether phacoemulsification is 
the future of cataract surgery. I think almost 
everyone would agree on a negative answer. 
Why? Because we already have it and use it 
regularly. It is not the “future” of cataract 
surgery, it is the current state. Although 
phacoemulsification has been a large progress Controversy; Sutureless Vitrectomy
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towards minimization of cataract surgery, 
everybody knows that phacoemulsification 
is still not the best minimal surgery and 
ophthalmologists are looking forward to 
enzyme-assisted phacolysis along with the 
injection of liquid IOLs as a realistic goal. The 
same also applies to sutureless vitrectomy 
techniques. These techniques present a state of 
the art procedure, and will certainly be a the 
predominant method for the next few years, 
but they are not the “future” of vitreoretinal 
surgery, just as phacoemulsification is not the 
future of cataract surgery. In my opinion, the 
future is in the hands of injections, along with 
preventive and personalized ophthalmology.
We now know that the vitreous is not only 
a clear substance for filling a cavity; it plays 
many physiological roles, the most clearly 
known is oxygen absorption and prevention 
of oxidative damage to intraocular structures.3 
Eyes undergoing vitrectomy are prone to the 
development of nuclear sclerotic cataracts 
and open angle glaucoma, probably due to 
augmented oxidative damage.4 Therefore 
removal of the vitreous may not always be 
desirable. If a treatment or preventive measure 
becomes available that by producing syneresis 
preserves gel vitreous, it will surely be a 
better option than surgery for many of current 
indications for vitrectomy.
A common saying in medicine is “prevention 
beats treatment”. Surely, progress in medical 
knowledge and resources will move the medical 
community more and more towards “preventive 
medicine”. To achieve prevention, one must 
first recognize those at risk, and personalized 
medicine will prove a powerful tool in this 
regard. In the personalized medical strategy, 
which is the beginning of a new era in all 
medical fields, information based on evaluation 
of genetic variations and expression profiles, 
proteins, and markers, is used to deliver targeted 
treatment or enforce prevention. Recognizing 
patients at risk for developing various diseases 
and obtaining knowledge on how the disease 
and the response to treatment is expressed or 
modified by the genetic background of the 
patient, are turning this idea into reality.5,6 
It is conceivable that in the future, we may 
be able to recognize genes causing abnormal 
vitreoretinal adhesions in patients developing 
vitreoretinal interface problems, macular holes, 
and retinal breaks after posterior vitreous 
detachment (PVD). We may even become able 
to recognize diabetics at risk of developing 
proliferative disease by evaluating their genetic 
background, and apply preventive measures 
in susceptible cases.
Chemical vitreolysis has drawn the attention 
of vitreoretinal surgeons for many years.7 Many 
agents have been examined in this regard: 
hyaluronidase8, autologous plasmin9,10, tissue 
plasminogen activator11,12, various enzymes13,14, 
and more recently, microplasmin15. But why 
chemical vitreolysis? Because injection is easier 
and less time-consuming than an operation, 
it creates a smoother surface with a lower 
risk of re-proliferation, and is less traumatic 
to the retina. Microplasmin is a synthetic 
recombinant form of truncated plasmin which 
cleaves fibronectin and laminin molecules at 
the vitreoretinal interface.16 In a randomized 
clinical trial, a single injection of microplasmin 
in eyes with vitreomacular traction, induced 
PVD in 44% of eyes 28 days after the injection, 
and in 58% after multiple injections.15 
With the discovery of additional targeted 
molecules, chemical vitreolysis will surely 
open its way as a safe and effective procedure. 
Targeted treatment to weaken the vitreoretinal 
junction without causing separation from the 
retina may become possible in the near future. 
This may have merit for prophylaxis against 
retinal break formation by PVD in susceptible 
eyes. Prevention of retinal break formation 
would circumvent one of the major indications 
for vitrectomy, i.e., retinal detachment and PVR. 
The same goal may prove desirable in those 
predisposed to macular hole formation and other 
vitreoretinal interface abnormalities. In other 
situations, such as diabetic retinopathy, it may 
be preferred to induce complete PVD in order 
to prevent new vessel growth into the vitreous 
cortex before development of proliferative 
retinopathy. By preventing proliferative diabetic 
retinopathy and its complications, one of the 
most common indications for vitrectomy will 
be avoided.Controversy; Sutureless Vitrectomy
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It seems that personalized medicine, 
along with advances in the field of chemical 
vitreolysis, will help ophthalmologists prevent 
many of the current indications for vitrectomy 
in the future. I admit that in spite of all the 
mentioned strategies, the need for vitrectomy 
surgery will remain for some cases.
Injections can also be used for other 
purposes, such as gene therapy, stem cell 
therapy, and the delivery of slow-release 
drug implants. These strategies may pave 
the road for treatment or prevention of many 
currently untreatable diseases, such as retinal 
degenerations and end-stage glaucoma.
With the preventive measures mentioned, 
hopefully only a few cases will require 
buckling surgery. Injectable and degradable 
materials are eligible candidates for use in 
scleral buckling. Polymers that are liquid at 
room temperature, but become solid at body 
temperature, can be injected into the globe 
overlying a retinal break with the guide of 
indirect ophthalmoscopy. These liquids can be 
made of biodegradable materials to minimize 
long-term anatomical alterations, such as corneal  
aberrations.17
Injections are simple, do not have a 
learning curve, do not need much anesthesia, 
are fast and cheap, and can be performed in 
outpatient settings. They are obviously much 
more acceptable to patients than surgery. They 
are much more efficient in terms of time and 
money, and are much less disturbing to the 
patient, care providers and the eye. This is why 
I consider them to be the future of vitreoretinal 
surgery.
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